Odimma Therapeutics
Empowering Personalized Immunotherapy to Treat Cancer
6 employees · est. 2017 · France
RareCan
RareCan aims to accelerate research and ultimately improve treatments and outcomes for people with rare cancers.
8 employees · est. 2019 · United Kingdom
Odimma Therapeutics is the older company (2017 vs 2019).
Side-by-Side Comparison
| Metric | Odimma Therapeutics | RareCan |
|---|---|---|
| Founded | ||
| Founded | 2017 older | 2019 |
| Headquarters | ||
| Headquarters | France | United Kingdom |
| Employees | ||
| Employees | 6 | 8 |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Seed | Equity Crowdfunding |
| Total Funding | ||
| Total Funding | $2.00M | $576.88K |
| Funding Rounds | ||
| Funding Rounds | 1 | 3 |
| Services | ||
| Services | Next-generation precision immunotherapy platform for personalized cancer treatment | Not tracked yet |
| Target Customers | ||
| Target Customers | Patients with hard-to-treat cancers, healthcare providers, research institutions | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Immunotherapy, Cancer Treatment, Precision Medicine, Immuno-oncology, Personalized Immunization, Neoantigens, Therapeutic Solutions, Onco-Immunology, Research & Development, DeepTech, Biotech, Clinical Trials, Therapeutic Efficacy, Cancer Immunotherapy, Patient-centric Approach | Rare Cancers, Clinical Trials, Patient Recruitment, Research Acceleration, Bio-samples, Genetic Data, NHS Trusts, Patient Organizations, Cancer Research, Data Access, Treatment Outcomes, Precision Cohort, Histology-independent Trials, Life Sciences Companies, Global Research Network |
| Website | ||
| Website | odimma-therapeutics.com | rarecan.com |
About Odimma Therapeutics
Odimma Therapeutics is a French biotech company specializing in active personalized cancer immunotherapy. They aim to improve the efficacy of current therapies by leveraging recent advances in immuno-oncology and harnessing the patient’s own immune system to recognize neoantigens displayed by the tu...
About RareCan
RareCan is a United Kingdom-based biotechnology and healthcare company, founded in 2019, with a mission to accelerate research and improve treatments for individuals with rare cancers. The company has recently secured a £374.88K Equity Crowdfunding investment on 15 June 2022 through Crowdcube. Rare...
We will tell you when either one moves
BounceWatch watches Odimma Therapeutics and RareCan for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Odimma Therapeutics and RareCan — by email.
Frequently Asked Questions
Compare Odimma Therapeutics with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Odimma Therapeutics on 7 Jun 2025, and RareCan on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.